Organon Foresees US Adalimumab Discounts Hitting 80%-90%

CEO Suggests Heavy Competition Will Lead To Steep Price Cuts By 2025-2026

 
• By Dave Wallace

Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.

Scissors cutting 100 dollar bill, discount concept
Humira biosimilar discounts could be substantial by 2025-2026 • Source: Shutterstock

More from Biosimilars

More from Products